Impax Reaches $20 Mln Deal to End Trial Over Generic Drug ' s Delay Impax Reaches $20 Mln Deal to End Trial Over Generic Drug ' s Delay

Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn.Reuters Health Information

Source: Medscape Medical News Headlines - March 30, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news